Breast cancer risk stratification using genetic and non-genetic risk assessment tools for 246,142 women in the UK Biobank

被引:11
|
作者
Ho, Peh Joo [1 ,2 ,3 ]
Lim, Elaine H. [4 ]
Hartman, Mikael [2 ,3 ,5 ]
Wong, Fuh Yong [6 ]
Li, Jingmei [1 ,2 ,7 ]
机构
[1] ASTAR Res Ent, Genome Inst Singapore, Lab Womens Hlth & Genet, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore, Singapore
[3] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore
[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Univ Surg Cluster, Dept Surg, Singapore, Singapore
[6] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore
[7] Genome Inst Singapore, 60 Biopolis St,Genome 02-01, Singapore 138672, Singapore
关键词
Breast cancer; Family history; Loss -of -function variants; Polygenic risk scores; Screening; POLYGENIC RISK; SCREENING MAMMOGRAPHY; PREDICTION MODELS; FAMILY-HISTORY; OLDER WOMEN; VALIDATION; DENSITY; SUSCEPTIBILITY; PROBABILITIES; INDIVIDUALS;
D O I
10.1016/j.gim.2023.100917
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: The benefit of using individual risk prediction tools to identify high-risk individuals for breast cancer (BC) screening is uncertain, despite the personalized approach of risk-based screening. Methods: We studied the overlap of predicted high-risk individuals among 246,142 women enrolled in the UK Biobank. Risk predictors assessed include the Gail model (Gail), BC family history (FH, binary), BC polygenic risk score (PRS), and presence of loss-of-function (LoF) variants in BC predisposition genes. Youden J-index was used to select optimal thresholds for defining high-risk. Results: In total, 147,399 were considered at high risk for developing BC within the next 2 years by at least 1 of the 4 risk prediction tools examined (Gail2-year > 0.5%: 47%, PRS2-yea r > 0.7%: 30%, FH: 6%, and LoF: 1%); 92,851 (38%) were flagged by only 1 risk predictor. The overlap between individuals flagged as high-risk because of genetic (PRS) and Gail model risk factors was 30%. The best-performing combinatorial model comprises a union of high-risk women identified by PRS, FH, and, LoF (AUC2-year [95% CI]: 62.2 [60.8 to 63.6]). Assigning individual weights to each risk prediction tool increased discriminatory ability. Conclusion: Risk-based BC screening may require a multipronged approach that includes PRS, predisposition genes, FH, and other recognized risk factors. & COPY; 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review
    Velentzis, Louiza S. S.
    Freeman, Victoria
    Campbell, Denise
    Hughes, Suzanne
    Luo, Qingwei
    Steinberg, Julia
    Egger, Sam
    Mann, G. Bruce
    Nickson, Carolyn
    CANCERS, 2023, 15 (04)
  • [22] Personalized Breast Cancer Risk Assessment: Incorporation of Genetic and High-Risk Factors on Breast Cancer Risk and Management
    Siettmann, Jennifer M.
    Arun, Banu
    Gasparini, Justin
    Mina, Lida A.
    CHIRURGIA, 2021, 116 (05) : S22 - S34
  • [23] Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery
    Irelli, Azzurra
    Patruno, Leonardo Valerio
    Ranieri, Sofia Chiatamone
    Di Giacomo, Daniela
    Malatesta, Sara
    Alesse, Edoardo
    Tessitore, Alessandra
    Cannita, Katia
    BIOMEDICINES, 2024, 12 (04)
  • [24] Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort
    Tran, Thi-Van-Trinh
    Maringe, Camille
    Benitez Majano, Sara
    Rachet, Bernard
    Boutron-Ruault, Marie-Christine
    Journy, Neige
    CANCER MEDICINE, 2021, 10 (13): : 4604 - 4614
  • [25] Association between triglyceride-glucose related indicators, genetic risk, and incident breast cancer among postmenopausal women in UK Biobank
    Zhen Li
    Zengle Zhao
    Tongchao Zhang
    Xiaorong Yang
    Hao Chen
    Xiaolin Yin
    Hao Bai
    Xinjie Liu
    Tongmin Chang
    Yuan Zhang
    Ming Lu
    BMC Cancer, 25 (1)
  • [26] Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study
    Kehm, Rebecca D.
    Hopper, John L.
    John, Esther M.
    Phillips, Kelly-Anne
    MacInnis, Robert J.
    Dite, Gillian S.
    Milne, Roger L.
    Liao, Yuyan
    Zeinomar, Nur
    Knight, Julia A.
    Southey, Melissa C.
    Vahdat, Linda
    Kornhauser, Naomi
    Cigler, Tessa
    Chung, Wendy K.
    Giles, Graham G.
    McLachlan, Sue-Anne
    Friedlander, Michael L.
    Weideman, Prue C.
    Glendon, Gord
    Nesci, Stephanie
    Andrulis, Irene L.
    Buys, Saundra S.
    Daly, Mary B.
    Terry, Mary Beth
    BREAST CANCER RESEARCH, 2019, 21 (1)
  • [27] Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women
    Juncheng Dai
    Zhibin Hu
    Yue Jiang
    Hao Shen
    Jing Dong
    Hongxia Ma
    Hongbing Shen
    Breast Cancer Research, 14
  • [28] Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women
    Shuai Lin
    Meng Wang
    Xinghan Liu
    Wenge Zhu
    Yan Guo
    Zhiming Dai
    Pengtao Yang
    Tian Tian
    Cong Dai
    Yi Zheng
    Chunyan Hu
    Linyan Wei
    Zhijun Dai
    Clinical and Experimental Medicine, 2017, 17 : 395 - 401
  • [29] GENETIC CANCER RISK ASSESSMENT FOR BREAST CANCER IN LATIN AMERICA
    Chavarri-Guerra, Yanin
    Blazer, Kathleen Reilly
    Weitzel, Jeffrey Nelson
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2017, 69 (02): : 94 - 102
  • [30] Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women
    Lin, Shuai
    Wang, Meng
    Liu, Xinghan
    Zhu, Wenge
    Guo, Yan
    Dai, Zhiming
    Yang, Pengtao
    Tian, Tian
    Dai, Cong
    Zheng, Yi
    Hu, Chunyan
    Wei, Linyan
    Dai, Zhijun
    CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 17 (03) : 395 - 401